Sight Sciences, Inc., (SGHT) News

Sight Sciences, Inc., (SGHT): $8.18

-0.29 (-3.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter SGHT News Items

SGHT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SGHT News Highlights

  • For SGHT, its 30 day story count is now at 5.
  • Over the past 13 days, the trend for SGHT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about SGHT are ESP, FLGT and MDT.

Latest SGHT News From Around the Web

Below are the latest news stories about Sight Sciences Inc that investors may wish to consider to help them evaluate SGHT as an investment opportunity.

Sight Sciences to Participate in the Upcoming Citi Virtual Healthcare Conference

MENLO PARK, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced plans to participate in the upcoming Citi Virtual Healthcare Conference. Sight Sciences’ management is scheduled to participate in a fireside chat February 23, 2022, at 8:45am PT. Interested parties may access a live and archived webcast of the fireside

Yahoo | February 21, 2022

Fulgent Genetics (FLGT) to Post Q4 Earnings: What's in Store?

In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.

Yahoo | February 21, 2022

Medtronic (MDT) to Report Q3 Earnings: What's in Store?

Medtronic (MDT) might report low procedure volumes in the fiscal third quarter in markets where its technologies are used in more deferrable procedures.

Yahoo | February 18, 2022

Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucoma

Educational campaign aims to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucomaMENLO PARK, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced the launch of its “Don’t Wait for Too Late” educational campaign designed to raise

Yahoo | February 17, 2022

Why Earnings Season Could Be Great for Sight Sciences (SGHT)

Sight Sciences (SGHT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | February 8, 2022

Insiders who bought Sight Sciences, Inc. (NASDAQ:SGHT) stock in the last 12 months recover some losses, but still down US$12k

Insiders who bought US$184k worth of Sight Sciences, Inc. ( NASDAQ:SGHT ) stock in the last year have seen some of...

Yahoo | January 13, 2022

Here's What Investors Need to Know About Sight Sciences Stock

In this segment of Backstage Pass, recorded on Dec. 13, 2021, Fool contributor Asit Sharma discusses a newly public healthcare stock that long-term investors may want to put on their radar right now. Asit Sharma: What is Sight Sciences (NASDAQ: SGHT)? This is a company founded in 2011 by two brothers, David and Paul Badawi.

Yahoo | January 12, 2022

The Bottom Is in for These 2 Stocks? Morgan Stanley Says ‘Buy’

The start of a new year is always a convenient time to evaluate, or reevaluate, the stock portfolios. With a year’s worth of data behind us, and fresh forecasts ahead, investors can use the fresh start on the calendar to figure out if they need a rethink on their investment strategy. In a note from Morgan Stanley, chief investment officer Mike Wilson defines the key question for investors now as a simple binary decision, between staying with relative winners or going ‘bottom fishing.’ Each has its supporters, but Wilson notes that, with no need to keep up with the market indexes, bottom fishing has an edge in January.

Michael Marcus on TipRanks | January 11, 2022

Should Investors Consider Sight Sciences Stock?

Sight Sciences (NASDAQ: SGHT) only recently made its public debut. Since the company's initial public offering last summer, shares have plunged by nearly 50%. Is this company, which markets medical devices to treat diseases of the eye, one that investors should put on their watch list right now?

Yahoo | January 11, 2022

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results

MENLO PARK, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced preliminary unaudited financial results for the fourth quarter and year ended December 31, 2021. Preliminary and Unaudited 2021 Financial Results Fourth quarter 2021 total revenue is expected to be in the range of $14.5 million to $14.8 million, an esti

Yahoo | January 10, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4669 seconds.